By Len Zehrs ASLAN Pharmaceuticals (NASDAQ:ASLN; TPEx:6497) expects to report topline and interim data in the second half of 2018 from up to four clinical trials with its lead drug candidate, varlitinib, for the...
By Melane Sampson For the first time in a century, administration of epidural needles is being transformed with a smart device developed by closely-held Omeq Medical, which has completed a proof of concept (POC)...
By Len Zehrs Centurion BioPharma, a newly-created private subsidiary of CytRx (NASDAQ:CYTR), is currently in discussions with a number of pharma companies for a strategic alliance to continue development of its patient...
By Len Zehrs Closely-held Intellijoint Surgical plans to improve patients’ lives by providing every orthopaedic surgeon with their surgical 3D solution that provides real-time intraoperative measurements to ensure...
By Len Zehrs Closely-held Kardium hopes to receive marketing approval in Europe in the fourth quarter of 2018 and launch its breakthrough Globe mapping and ablation system of cardiac tissue for the treatment of atrial...
By Len Zehrs Imagin Medical’s (CSE:IME; OTC:IMEXF) i/Blue Imaging System is expected to improve physicians’ ability to detect bladder cancer with minimally invasive endoscopes and reduce recurrence by dramatically...
By Len Zehrs Closely-held XOR Labs hopes to dramatically increase the number of lungs suitable for transplantation with its Ex-Vivo Lung Perfusion (EVLP) technology. “Only about 20 out of every 100 donated lungs are...
By Len Zehrs NanoSphere Health Sciences (CSE:NSHS; OTC:NSHSF) has developed a newly-patented delivery technology that increases the bioavailability and bioactivity of its Evolve line of gel-like cannabinoids for the...
By Melane Sampson Since developing and validating SETALUM, a versatile vascular sealant in 2013, closely-held, Paris-based Gecko Biomedical is now poised to seek FDA approval for SETALUM, validate new programs, and open...
By Len Zehrs France’s Nanobiotix (Euronext:NANO) is hoping to change the paradigm for cancer treatment with a single nanomedicine applicable across oncology for millions of patients. “What differentiates us is that we...